Recent Publications

Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer.
Robertson AG, et al. Among authors: meeks jj.
Nat Commun. 2023 Apr 27;14(1):2126. doi: 10.1038/s41467-023-37568-9.
A vision for closing the evidence-practice gap in the management of low-grade prostate cancer.
Leapman MS, Loeb S, Cooperberg MR, Catalona WJ, Gaylis FD.
JNCI Cancer Spectr. 2023 Mar 1;7(2):pkad028. doi: 10.1093/jncics/pkad028.
Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314.
Lu YT, et al. Among authors: meeks jj.
Eur Urol Oncol. 2023 Apr 20:S2588-9311(23)00074-3. doi: 10.1016/j.euo.2023.03.008. Online ahead of print.
The past, present and future of ACS NSQIP-Pediatric: Evolution from a quality registry to a comparative quality performance platform.
Saito JM, et al. Among authors: johnson ek.
Semin Pediatr Surg. 2023 Apr 11;32(2):151275. doi: 10.1016/j.sempedsurg.2023.151275. Online ahead of print.
A novel prostate cancer subtyping classifier based on luminal and basal phenotypes.
Weiner AB, et al. Among authors: schaeffer em.
Cancer. 2023 Apr 14. doi: 10.1002/cncr.34790. Online ahead of print.
Disparities in access to robotic technology and perioperative outcomes among patients treated with radical prostatectomy.
Logan CD, Mahenthiran AK, Siddiqui MR, French DD, Hudnall MT, Patel HD, Murphy AB, Halpern JA, Bentrem DJ.
J Surg Oncol. 2023 Apr 10. doi: 10.1002/jso.27274. Online ahead of print.
Study protocol for a prospective, multi-centered randomized controlled trial comparing pelvic fascia-sparing radical prostatectomy with conventional robotic-assisted prostatectomy: The PARTIAL trial.
Stangl-Kremser J, Kowalczyk K, Schaeffer EM, Allaf M, Scherr D, Yang X, Matoso A, Azumi N, Robinson B, Vickers A, Hu JC.
Contemp Clin Trials. 2023 Apr 2;128:107168. doi: 10.1016/j.cct.2023.107168. Online ahead of print.
Robot-Assisted Laparoscopic Pyeloplasty: Experience of a Single Pediatric Institution, including Long-Term and Safety Outcomes.
Lai A, Shannon R, Rosoklija I, Johnson EK, Gong EM, Chu DI, Lindgren BW.
Urology. 2023 Mar 31:S0090-4295(23)00296-0. doi: 10.1016/j.urology.2022.12.070. Online ahead of print.
Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease.
Rose KM, et al. Among authors: meeks jj.
Nat Rev Urol. 2023 Mar 28. doi: 10.1038/s41585-023-00725-2. Online ahead of print.
Optimizing detection of clinically significant prostate cancer through nomograms incorporating mri, clinical features, and advanced serum biomarkers in biopsy naïve men.
Siddiqui MR, et al. Among authors: schaeffer em.
Prostate Cancer Prostatic Dis. 2023 Mar 27. doi: 10.1038/s41391-023-00660-8. Online ahead of print.